| Name | ML351 |
| Description | ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM). |
| In vitro | ML351 exhibited nanomolar potency and excellent selectivity (>250-fold) versus 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. In mouse neuronal HT22 cells, ML351 dose-dependently protected against oxidative glutamate toxicity and completely reversed the increase in 12-HETE following glutamate treatment [2][3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% (20% SBE-β-CD in Saline) : < 5 mg/mL (20.06 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Corn Oil : 2 mg/mL (8.02 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : < 5 mg/mL (20.06 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Saline : < 5 mg/mL (20.06 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
DMSO : 50 mg/mL (200.59 mM), Sonication is recommended.
10% DMSO+90% Corn oil : 5 mg/mL (20.06 mM), Solution.
|
| Keywords | β-cell | T1D | Subarachnoid hemorrhage | SAH | oxidative stress | non-obese diabetic | neuronal | ML-351 | ML351 | ML 351 | LOX | Lipoxygenase | Inhibitor | inhibit | 15 LOX |
| Inhibitors Related | 2,5-Di-tert-butylhydroquinone | Caffeic Acid | 5-LOX inhibitor | 3-Aminobutanoic acid | Phenidone | 4-Aminosalicylic acid | Cuminaldehyde | NNK | Shogaol | Malotilate | 5-Aminosalicylic Acid | Tebufelone |
| Related Compound Libraries | Ferroptosis Compound Library | Nonsteroidal Anti-Inflammatory Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Anti-Obesity Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Metabolism Disease Compound Library |
United States
